Cite
HARVARD Citation
Yamazaki, K. et al. (n.d.). 365 Identification of the recommended phase II dose (RP2D) of the c-Met Inhibitor tepotinib (MSC2156119J) in Japanese patients (pts) with solid tumors: A phase I trial. European journal of cancer. pp. S75-S76. [Online].